Bootstrap Bio and Manhattan Genomics, two companies focused on human embryo editing to prevent genetic diseases, have ceased operations. The closures mark a setback for the controversial field of germline editing.
Bootstrap Bio and Manhattan Genomics have both shut down their operations, ending their respective efforts to develop human embryo editing technologies. The companies were among a small number of firms pursuing germline editing—modifications to embryos that would be inherited by future generations—primarily to prevent serious genetic conditions.
The reasons behind the closures were not immediately detailed, but the exits underscore the commercial and regulatory challenges facing the embryo editing sector. The field has faced intense scrutiny from bioethicists, policymakers, and the public since Chinese scientist He Jiankui's 2018 announcement of the first gene-edited babies, which triggered global controversy and criminal charges against him.
The U.S. and many other countries have restricted or banned germline editing in humans. While some researchers continue work on somatic gene therapy—editing non-reproductive cells—the commercial viability of human embryo editing remains highly uncertain.
Town, an enterprise personal AI assistant platform, is in talks to raise funding at a $1 billion valuation in a round led by Index Ventures, according to sources.
Product management platform Linear reached $100M in annual recurring revenue and conducted a $99M employee tender offer at a $2.5B valuation, doubling its valuation from $1.25B in 2025.
Flipboard is acquiring Bluesky feed-building startup Graze, integrating its ad technology and creator monetization tools into its open social web platform.
Artificial intelligence is fundamentally changing how startups operate, not just what they build. According to Floodgate co-founder Ann Miura-Ko, companies are deploying AI agents across engineering, sales, marketing, and strategy to accelerate learning and execution.